Waldemar Priebe

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10432053/publications.pdf

Version: 2024-02-01

156 papers	6,887 citations	53794 45 h-index	69250 77 g-index
156 all docs	156 docs citations	156 times ranked	8767 citing authors

#	Article	IF	Citations
1	Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro-Oncology, 2010, 12, 1113-1125.	1.2	530
2	2-Deoxy-d-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers In Vivo. Cancer Research, 2004, 64, 31-34.	0.9	414
3	A Novel Small Molecule Inhibitor of Signal Transducers and Activators of Transcription 3 Reverses Immune Tolerance in Malignant Glioma Patients. Cancer Research, 2007, 67, 9630-9636.	0.9	278
4	Glioblastoma Cancer-Initiating Cells Inhibit T-Cell Proliferation and Effector Responses by the Signal Transducers and Activators of Transcription 3 Pathway. Molecular Cancer Therapeutics, 2010, 9, 67-78.	4.1	253
5	Parsing the Free Energy of Anthracycline Antibiotic Binding to DNAâ€. Biochemistry, 1996, 35, 2047-2053.	2.5	187
6	Activation of Signal Transducers and Activators of Transcription 3 and Focal Adhesion Kinase by Stromal Cell-Derived Factor 1 Is Required for Migration of Human Mesenchymal Stem Cells in Response to Tumor Cell-Conditioned Medium. Stem Cells, 2009, 27, 857-865.	3.2	182
7	Hypoxia Potentiates Glioma-Mediated Immunosuppression. PLoS ONE, 2011, 6, e16195.	2.5	177
8	The Incidence, Correlation with Tumor-Infiltrating Inflammation, and Prognosis of Phosphorylated STAT3 Expression in Human Gliomas. Clinical Cancer Research, 2008, 14, 8228-8235.	7.0	174
9	Structure-Based Design of a New Bisintercalating Anthracycline Antibiotic. Journal of Medicinal Chemistry, 1997, 40, 261-266.	6.4	150
10	WP1066 Disrupts Janus Kinase-2 and Induces Caspase-Dependent Apoptosis in Acute Myelogenous Leukemia Cells. Cancer Research, 2007, 67, 11291-11299.	0.9	127
11	Mitotic Catastrophe Results in Cell Death by Caspase-Dependentand Caspase-Independent Mechanisms. Cell Cycle, 2006, 5, 53-60.	2.6	123
12	Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin. Biochemical Pharmacology, 2007, 73, 620-631.	4.4	118
13	Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer, 2011, 117, 2926-2938.	4.1	112
14	A Novel Inhibitor of Signal Transducers And Activators Of Transcription 3 Activation Is Efficacious Against Established Central Nervous System Melanoma and Inhibits Regulatory T Cells. Clinical Cancer Research, 2008, 14, 5759-5768.	7.0	111
15	Ultratight DNA Binding of a New Bisintercalating Anthracycline Antibiotic. Biochemistry, 1998, 37, 1743-1753.	2.5	109
16	Quantitative Phosphoproteomic Analysis of the STAT3/IL-6/HIF1Î± Signaling Network: An Initial Study in GSC11 Glioblastoma Stem Cells. Journal of Proteome Research, 2010, 9, 430-443.	3.7	99
17	A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance. Investigational New Drugs, 2007, 25, 313-326.	2.6	89
18	Synthesis of alkyl 4,6-di-o-acetyl-2,3-dideoxy-Î±-d-threo-hex-2- enopyranosides from 3,4,6-tri-o-acetyl-1,5-anhydro-2-deoxy- d-lyxo-hex-1-enitol (3,4,6-tri-o-acetyl-d-galactal). Carbohydrate Research, 1979, 68, 33-41.	2.3	85

#	Article	IF	Citations
19	Evidence that activation of nuclear factor-ÎºB is essential for the cytotoxic effects of doxorubicin and its analogues. Biochemical Pharmacology, 2004, 67, 353-364.	4.4	83
20	Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood, 2007, 109, 3470-3478.	1.4	82
21	Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochemical Pharmacology, 2002, 64, 1745-1751.	4.4	77
22	Inhibition of the JAK2/STAT3 Pathway Reduces Gastric Cancer Growth In Vitro and In Vivo. PLoS ONE, 2014, 9, e95993.	2.5	77
23	Doxorubicin- and Daunorubicin-Glutathione Conjugates, but Not Unconjugated Drugs, Competitively Inhibit Leukotriene C4Transport Mediated byMRP/GS-XPump. Biochemical and Biophysical Research Communications, 1998, 247, 859-863.	2.1	76
24	WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F Mutation. Clinical Cancer Research, 2008, 14, 788-796.	7.0	76
25	A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunology, Immunotherapy, 2009, 58, 1023-1032.	4.2	74
26	Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro-Oncology, 2012, 14, 1136-1145.	1.2	73
27	The Overall Partitioning of Anthracyclines into Phosphatidyl-Containing Model Membranes Depends Neither on the Drug Charge Nor the Presence of Anionic Phospholipids. FEBS Journal, 1996, 241, 879-887.	0.2	72
28	Intratumoral Mediated Immunosuppression is Prognostic in Genetically Engineered Murine Models of Glioma and Correlates to Immunotherapeutic Responses. Clinical Cancer Research, 2010, 16, 5722-5733.	7.0	71
29	Efficacy of 2-halogen substituted d-glucose analogs in blocking glycolysis and killing â€œhypoxic tumor cellsâ€• Cancer Chemotherapy and Pharmacology, 2006, 58, 725-734.	2.3	67
30	Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity. Anti-Cancer Drugs, 1993, 4, 37-48.	1.4	66
31	Binding of Two Novel Bisdaunorubicins to DNA Studied by NMR Spectroscopyâ€,â€¡. Biochemistry, 1997, 36, 8663-8670.	2.5	66
32	In Vitro Evaluation of Photosensitivity Risk Related to Genetic Polymorphisms of Human ABC Transporter ABCG2 and Inhibition by Drugs. Drug Metabolism and Pharmacokinetics, 2007, 22, 428-440.	2.2	66
33	Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway. Journal of Neuro-Oncology, 2012, 107, 487-501.	2.9	64
34	The acid-catalysed reaction of thiols with alkyl 2,3-dideoxy-glyc-2-enopyranosides or glycals. Tetrahedron, 1980, 36, 287-297.	1.9	63
35	Structure of a DNAâ^'Bisdaunomycin Complexâ€,â€¡. Biochemistry, 1997, 36, 5940-5946.	2.5	60
36	Iodoalkoxylation of 1,5-anhydro-2-deoxy-hex-1-enitols (glycals). Carbohydrate Research, 1990, 205, 71-86.	2.3	59

#	Article	IF	Citations
37	Analysis of Drug Transport Kinetics in Multidrug-resistant Cells: Implications for Drug Action. Current Medicinal Chemistry, 2001, 8, 51-64.	2.4	59
38	Base Specific and Regioselective Chemical Cross-Linking of Daunorubicin to DNA. Journal of the American Chemical Society, 1996, 118, 4731-4738.	13.7	55
39	Allylic rearrangement of 6-deoxyglycals having practical utility. Carbohydrate Research, 1985, 144, 331-337.	2.3	53
40	A New Bisintercalating Anthracycline with Picomolar DNA Binding Affinity. Journal of Medicinal Chemistry, 2005, 48, 8209-8219.	6.4	53
41	Design and tumor targeting of anthracyclines able to overcome multidrug resistance: A double-advantage approach. , 1993, 60, 215-234.		51
42	Degrasyn Potentiates the Antitumor Effects of Bortezomib in Mantle Cell Lymphoma Cells In vitro and In vivo: Therapeutic Implications. Molecular Cancer Therapeutics, 2010, 9, 2026-2036.	4.1	51
43	Inhibition of p-STAT3 Enhances IFN-Î± Efficacy against Metastatic Melanoma in a Murine Model. Clinical Cancer Research, 2010, 16, 2550-2561.	7.0	51
44	Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells. Oncotarget, 2015, 6, 10016-10029.	1.8	50
45	IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. Journal of the National Cancer Institute, 2016, 108, djw182.	6.3	49
46	Analysis of the Effects of Daunorubicin and WP631 on Transcription. Current Medicinal Chemistry, 2001, 8, 1-8.	2.4	46
47	The Inhibitory Effect of 2-Halo Derivatives of d-Glucose on Glycolysis and on the Proliferation of the Human Malaria Parasite Plasmodium falciparum. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 511-517.	2.5	45
48	Synthetic routes to higher-carbon sugars. Reaction of lactones with 2-lithio-,3-dithiane. Carbohydrate Research, 1981, 94, 27-41.	2.3	43
49	Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein. Biochimica Et Biophysica Acta - Molecular Cell Research, 1999, 1450, 374-384.	4.1	42
50	Differential Sensitivity to 2-Deoxy-D-glucose Between Two Pancreatic Cell Lines Correlates With GLUT-1 Expression. Pancreas, 2005, 30, e34-e39.	1.1	40
51	Effect of vesicle size and lipid composition on thein vivo tumor selectivity and toxicity of the non-cross-resistant anthracycline annamycin incorporated in liposomes. International Journal of Cancer, 1995, 61, 666-671.	5.1	39
52	Interaction of doxorubicin and its derivatives with DNA: Elucidation by resonance Raman and surface-enhanced resonance Raman spectroscopy. Biospectroscopy, 1997, 3, 307-316.	0.6	39
53	A novel small molecule deubiquitinase inhibitor blocks Jak2 signaling through Jak2 ubiquitination. Cellular Signalling, 2011, 23, 2076-2085.	3.6	38
54	Radiation with STAT3 Blockade Triggers Dendritic Cellâ€“T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy. Clinical Cancer Research, 2020, 26, 4983-4994.	7.0	38

#	Article	IF	Citations
55	New findings in the study on the intercalation of bisdaunorubicin and its monomeric analogues with naked and nucleus DNA. Chemico-Biological Interactions, 2003, 145, 349-358.	4.0	37
56	The tumor microenvironment expression of pâ€šSTAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. International Journal of Cancer, 2012, 131, 8-17.	5.1	36
57	Ï0 tumor cells: a model for studying whether mitochondria are targets for rhodamine 123, doxorubicin, and other drugs. Biochemical Pharmacology, 2000, 60, 1897-1905.	4.4	35
58	Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells. Cancer Biology and Therapy, 2012, 13, 657-670.	3.4	35
59	P-Glycoprotein preferentially effluxes anthracyclines containing free basic versus charged amine. FEBS Journal, 2001, 268, 1561-1567.	0.2	34
60	Glycomic and Transcriptomic Response of GSC11 Glioblastoma Stem Cells to STAT3 Phosphorylation Inhibition and Serum-Induced Differentiation. Journal of Proteome Research, 2010, 9, 2098-2108.	3.7	34
61	Induction of G2/M arrest and inhibition of c-myc and p53 transcription by WP631 in Jurkat T lymphocytes. Biochemical Pharmacology, 2002, 63, 1251-1258.	4.4	32
62	Regulation of HGF Expression by Î”EGFR-Mediated c-Met Activation in Glioblastoma Cells. Neoplasia, 2013, 15, 73-IN21.	5.3	32
63	How Does the MRP/GS-X Pump Export Doxorubicin?. Journal of the National Cancer Institute, 1995, 87, 1639-1640.	6.3	31
64	Halogenation of 1,5-anhydrohex-1-enitols (glycals). Influence of the C-6 substituent. Journal of Organic Chemistry, 1986, 51, 3479-3485.	3.2	29
65	Exploiting anthracycline scaffold for designing DNA-targeting agents. Methods in Enzymology, 2001, 340, 529-555.	1.0	29
66	Synthesis and antitumor activity of 3'-deamino-3'-hydroxydoxorubicin. A facile procedure for the preparation of doxorubicin analogs.. Journal of Antibiotics, 1984, 37, 853-858.	2.0	28
67	Synthesis and antitumor activity of 7-O-(3,4-di-O-acetyl-2,6-dideoxy-Î±-l-lyxo-hexopyranosyl)adriamycinone. Carbohydrate Research, 1981, 94, 11-25.	2.3	26
68	Therapeutic suppression of constitutive and inducible JAKSTAT activation in head and neck squamous cell carcinoma. Journal of Experimental Therapeutics and Oncology, 2009, 8, 117-27.	0.5	25
69	Sp1-Targeted Inhibition of Gene Transcription by WP631 in Transfected Lymphocytesâ€. Biochemistry, 2004, 43, 7584-7592.	2.5	24
70	Modeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model of Ewing Sarcoma. Tissue Engineering - Part A, 2017, 23, 80-89.	3.1	24
71	Selective silylation of 6-deoxyglycals. Carbohydrate Research, 1985, 144, 325-330.	2.3	23
72	Oxyhalogenation of glycals for the synthesis of anti-tumor-active 2â€²-halo daunorubicin analogs. Carbohydrate Research, 1985, 136, 391-396.	2.3	23

#	Article	IF	Citations
73	P-glycoprotein-mediated efflux of hydroxyrubicin, a neutral anthracycline derivative, in resistant K562 cells. FEBS Letters, 1994, 356, 287-290.	2.8	23
74	Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers. Recent Patents on CNS Drug Discovery, 2008, 3, 179-188.	0.9	23
75	Selective acylation of 6-deoxyglycals. Carbohydrate Research, 1985, 144, 317-324.	2.3	22
76	A comparative analysis of the time-dependent antiproliferative effects of daunorubicin and WP631. FEBS Journal, 2003, 270, 764-770.	0.2	22
77	2-Deoxy-1-O-silylated-Î²-hexopyranoses. Useful glycosyl donors and synthetic intermediates.. Tetrahedron Letters, 1991, 32, 2079-2082.	1.4	21
78	d-Glucose- and d-mannose-based antimetabolites. Part 2. Facile synthesis of 2-deoxy-2-halo-d-glucoses and -d-mannoses. Carbohydrate Research, 2009, 344, 1464-1473.	2.3	21
79	Therapeutic targets in subependymoma. Journal of Neuroimmunology, 2014, 277, 168-175.	2.3	21
80	Synthesis of antitumor-active (7S,9S)-4-demethoxy-7-O-(2,6-dideoxy-2-iodo-Î±-l-mannopyranosyl)adriamycinone: Preparative resolution of a racemic anthracyclinone by alkoxyhalogenation of a glycal. Carbohydrate Research, 1984, 130, C1-C3.	2.3	20
81	Synthesis and antitumor activity of 2â€²-bromo- and 2â€²-chloro-3â€²-acetoxy-3â€²-deaminodaunorubicin analogs. Carbohydrate Research, 1985, 144, 305-315.	2.3	20
82	Circumvention of the multidrug-resistance protein (MRP-1) by an antitumor drug through specific inhibition of gene transcription in breast tumor cells. Biochemical Pharmacology, 2007, 73, 934-942.	4.4	20
83	d-Glucose and d-mannose-based metabolic probes. Part 3: Synthesis of specifically deuterated d-glucose, d-mannose, and 2-deoxy-d-glucose. Carbohydrate Research, 2013, 368, 111-119.	2.3	19
84	WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML). Anticancer Research, 2005, 25, 1841-50.	1.1	19
85	3'-Deamino-4'-epi-3'-hydroxy-daunorubicin and -doxorubicin. Synthesis and antitumor activity.. Journal of Antibiotics, 1984, 37, 1635-1641.	2.0	18
86	Organ distribution and tumor uptake of annamycin, a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesicles. Cancer Chemotherapy and Pharmacology, 1993, 32, 190-196.	2.3	18
87	Steric and conformational effects in the dehalogenation of 2-halo sugar derivatives with tributylstannane. Journal of Organic Chemistry, 1993, 58, 1821-1826.	3.2	18
88	Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide. International Journal of Cancer, 1997, 71, 35-41.	5.1	18
89	Transcriptional changes facilitate mitotic catastrophe in tumour cells that contain functional p53. European Journal of Pharmacology, 2006, 540, 34-45.	3.5	18
90	Lyophilized preliposomal formulation of the non-cross-resistant anthracycline annamycin: effect of surfactant on liposome formation, stability and size. Cancer Chemotherapy and Pharmacology, 1996, 39, 103-108.	2.3	17

#	Article	IF	Citations
91	Importance of Sp1 consensus motifs in the MYCN promoter. Surgery, 2002, 132, 232-238.	1.9	17
92	Preferential efflux by P-glycoprotein, but not MRP1, of compounds containing a free electron donor amine. Biochemical Pharmacology, 2002, 63, 1471-1479.	4.4	17
93	Integrative Biological Analysis For Neuropsychopharmacology. Neuropsychopharmacology, 2014, 39, 5-23.	5.4	17
94	A facile method for preparation of 3-thio-sugars and 3-thio-glycals. synthesis of 3â€²-mercapto-3â€²-deamino-doxorubicin. Tetrahedron Letters, 1991, 32, 3313-3316.	1.4	16
95	Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance. International Journal of Cancer, 1994, 58, 85-94.	5.1	15
96	Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells. Cancer Chemotherapy and Pharmacology, 1994, 34, 109-118.	2.3	15
97	Hydroxylation at C-3â€² of doxorubicin alters the selected phenotype of cellular drug resistance. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 1807-1812.	2.2	15
98	Differential toxic effect ofcis-platinum(II) and palladium(II) chlorides complexed with methyl 3,4-diamine-2,3,4,6-tetradeoxy-?-L-lyxo-hexopyranoside in mouse lymphoma cell lines differing in DSB and NER repair ability. Teratogenesis, Carcinogenesis, and Mutagenesis, 2003, 23, 1-11.	0.8	15
99	Effect of structural modification at the 4, 3â€², and 2â€² positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells. Archivum Immunologiae Et Therapiae Experimentalis, 2007, 55, 193-198.	2.3	15
100	A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer. Cancer Chemotherapy and Pharmacology, 2011, 68, 1033-1044.	2.3	15
101	Hyperpolarized Pyruvate MR Spectroscopy Depicts Glycolytic Inhibition in a Mouse Model of Glioma. Radiology, 2019, 293, 168-173.	7.3	15
102	A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncology, 2022, 11, CNS87.	3.0	15
103	Drug sequestration in cytoplasmic organelles does not contribute to the diminished sensitivity of anthracyclines in multidrug resistant K562 cells. FEBS Journal, 2001, 268, 4459-4467.	0.2	14
104	Simple, semiautomatic assay of cytostatic and cytotoxic effects of antitumor drugs by laser scanning cytometry: Effects of the bis-intercalator WP631 on growth and cell cycle of T-24 cells. Cytometry, 2004, 57A, 113-119.	1.8	14
105	DFT Study on the Selectivity of Complexation of Metal Cations with a Dioxadithia Crown Ether Ligand. Journal of Physical Chemistry A, 2008, 112, 13633-13640.	2.5	14
106	Development of novel molecular probes of the Rio1 atypical protein kinase. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 1292-1301.	2.3	14
107	The 4â€²-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells. Investigational New Drugs, 2006, 25, 115-122.	2.6	13
108	A Bisanthracycline (WP631) Represses uPAR Gene Expression and Cell Migration of RKO Colon Cancer Cells by Interfering With Transcription Factor Binding to a Chromatin-Accessible â^'148/â^'124 Promoter Region. Oncology Research, 2005, 15, 265-279.	1.5	13

#	Article	IF	Citations
109	Structure and biological activity of cationic [PtLCl(DMSO)]NO3Â·DMSO complex containing a chelated diaminosugar: methyl-3,4-diamino-2,3,4,6-tetradeoxy-Î±-l-lyxopyranoside. European Journal of Medicinal Chemistry, 2003, 38, 775-780.	5.5	11
110	Sequence selective binding of bis-daunorubicin WP631 to DNA. FEBS Journal, 2004, 271, 3556-3566.	0.2	11
111	Novel molecular multilevel targeted antitumor agents. Cancer Translational Medicine, 2017, 3, 69.	0.2	11
112	Enhanced topoisomerase II targeting by annamycin and related 4-demethoxy anthracycline analogues. Molecular Cancer Therapeutics, 2004, 3, 1403-10.	4.1	11
113	Liposomal formulation and antitumor activity of 14-O-palmitoyl-hydroxyrubicin. Cancer Chemotherapy and Pharmacology, 1992, 30, 267-271.	2.3	10
114	Synthesis and antitumor activity of anthracycline disaccharide glycosides containing daunosamine.. Journal of Antibiotics, 1993, 46, 1720-1730.	2.0	10
115	Comparison of DNA sequence selectivity of anthracycline antibiotics and their 3â€²-hydroxylated analogs. Chemico-Biological Interactions, 1996, 100, 165-176.	4.0	10
116	A new approach to 2-deoxyglycosides permitting access to anthracycline glycosides specifically labeled at the 2â€²-position. Carbohydrate Research, 1989, 187, 149-153.	2.3	9
117	One step C-acylation of glycals and 2-deoxy-hexopyranoses at C-2. Tetrahedron Letters, 1992, 33, 7681-7684.	1.4	9
118	Substitutions at C2' of Daunosamine in the Anticancer Drug Daunorubicin Alter Its DNA-Binding Sequence Specificity. FEBS Journal, 1996, 240, 331-335.	0.2	9
119	WP744 is a novel anthracycline with enhanced activity against neuroblastoma1. Journal of Surgical Research, 2004, 121, 187-196.	1.6	9
120	New adriamycin analogs. Synthesis and antitumor activity of 14-substituted 7-O-(3,4-di-O-acetyl-2,6-dideoxy-.ALPHA.-l-lyxo-hexopyranosyl)daunomycinones.. Journal of Antibiotics, 1981, 34, 1019-1025.	2.0	8
121	Complexation of Metal Ions in Langmuir Films Formed with Two Amphiphilic Dioxadithia Crown Ethers. Journal of Physical Chemistry B, 2008, 112, 10953-10963.	2.6	8
122	Formation and Reactions of Glycal Derivatives. , 2001, , 749-783.		8
123	Maximizing Local Access to Therapeutic Deliveries in Glioblastoma. Part I: Targeted Cytotoxic Therapy. , 0, , 341-358.		8
124	Relationship between topoisomerase II-DNA cleavable complexes, apoptosis and cytotoxic activity of anthracyclines in human cervix carcinoma cells. Anticancer Research, 2005, 25, 2193-8.	1.1	8
125	Preparation of 4-O-acetyl-1,5-anhydro-2,3,6-trideoxy-3-trifluoroacetamido-l- lyxo-hex-1-enitol, a key intermediate in synthesis of daunosamine glycosides. Carbohydrate Research, 1989, 187, 145-148.	2.3	7
126	3'-Hydroxyesorubicin. Synthesis and antitumor activity.. Journal of Antibiotics, 1990, 43, 838-846.	2.0	7

#	Article	IF	Citations
127	The influence of stereoselective P-glycoprotein- and multidrug resistance-associated protein-mediated transport of daunorubicin11Abbreviations: P-gp, P-glycoprotein; MRP1, multidrug resistance-associated protein; DNR, daunorubicin; WP900, daunorubicin enantiomer; Ci, intracellular free drug concentration in the cytosol; Ce: extracellular free drug concentration; Cn1, overall concentration of drug accumulated inside the cell (in the nucleus and in the acidic compartment); Cn, overall concentration of drug boun. Biochemical Pharmacology, 2001, 62, 561-567.	4.4	7
128	Glycal Derivatives. , 2008, , 699-735.		7
129	Drug Conjugates for Targeting Eph Receptors in Glioblastoma. Pharmaceuticals, 2020, 13, 77.	3.8	7
130	Synergistic Anticancer Effect of Glycolysis and Histone Deacetylases Inhibitors in a Glioblastoma Model. Biomedicines, 2021, 9, 1749.	3.2	7
131	14-Esters of 7-O-(3,4-di-O-acetyl-2,6-dideoxy-.ALPHA.-L-lyxo-hexopyranosyl)adriamycinone: synthesis and antitumor activity.. Journal of Antibiotics, 1983, 36, 1211-1215.	2.0	6
132	Partial circumvention of multi-drug resistance by annamycin is associated with comparable inhibition of DNA synthesis in the nuclear matrix of sensitive and resistant cells. International Journal of Cancer, 1995, 61, 402-408.	5.1	6
133	3'-Hydroxyesorubicin halogenated at C-2'.. Journal of Antibiotics, 1992, 45, 386-393.	2.0	5
134	Quantitative Analysis of the Lipophilic Doxorubicin Analogue Annamycin in Plasma and Tissue Samples by Reversed-Phase Chromatography. Journal of Pharmaceutical Sciences, 1993, 82, 1151-1154.	3.3	5
135	Synthesis of 3-deoxyaldulosonic acid esters by one-carbon chain extension of glycal-derived lactone precursors. Carbohydrate Research, 1993, 246, 105-118.	2.3	5
136	WP760, a melanoma selective drug. Cancer Chemotherapy and Pharmacology, 2007, 60, 625-633.	2.3	5
137	Structure and dynamics of methyl cis-3,4-diamino-2,3,4,6-tetradeoxy-Î±-l-lyxo-hexopyranoside complexes with PtCl2 and PdCl2, by 1H, 2H, 13C, 15N and 195Pt NMR spectroscopy in DMSO, CD3CN and H2O. Dalton Transactions, 2008, , 4129.	3.3	5
138	Bromine Atom Interactions in Biologically Active Acrylamide Derivatives. Crystal Growth and Design, 2015, 15, 2632-2642.	3.0	5
139	Experimental and Computational Studies on Structure and Energetic Properties of Halogen Derivatives of 2-Deoxy-D-Glucose. International Journal of Molecular Sciences, 2021, 22, 3720.	4.1	5
140	Topoisomerase II alpha expression and cytotoxicity of anthracyclines in human neoplastic cells. Acta Poloniae Pharmaceutica, 2006, 63, 15-8.	0.1	5
141	Preparative procedures for conversion of daunorubicin into doxorubicin (Adriamycin) and 14-O-acetyldoxorubicin by way of 14-bromodaunorubicin. Carbohydrate Research, 1988, 184, 231-235.	2.3	4
142	Synthesis of new 1-C-(2-furyl)-and 3-C-(2-furyl)-hexopyranosides and 3-C-(2-furyl)-daunorubicin analogs. Monatshefte FÃ¼r Chemie, 1991, 122, 419-423.	1.8	4
143	Multidrug resistance protein functionality: no effect of intracellular or extracellular pH changes. Biochemical Pharmacology, 2000, 60, 1485-1489.	4.4	4
144	The Ability of New Sugar-Modified Derivatives of Antitumor Anthracycline, Daunorubicin, to Stimulate NAD(P)H Oxidation in Different Cellular Oxidoreductase Systems: NADH Dehydrogenase, NADPH Cytochrome P450 Reductase, and Xanthine Oxidase. Oncology Research, 2004, 14, 469-474.	1.5	4

#	Article	IF	Citations
145	Autophagy modulates the effects of bisâ€anthracycline WP 631 on p53â€deficient prostate cancer cells. Journal of Cellular and Molecular Medicine, 2015, 19, 786-798.	3.6	4
146	Antitumor Activity and Mechanism of Action of a Novel Stat3 Inhibitor, WP1066, Against Human B-Cell Non-Hodgkinâ€™s Lymphoma and Multiple Myeloma.. Blood, 2005, 106, 1489-1489.	1.4	4
147	Activation of a Novel Proteasomal Independent Bcr/Abl Degradation Pathway by WP1130 Induces Apoptosis in CML Cells.. Blood, 2005, 106, 2862-2862.	1.4	4
148	Changes in gene expression induced by Sp1 knockdown differ from those caused by challenging Sp1 binding to gene promoters. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2011, 1809, 327-336.	1.9	3
149	Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation. Investigational New Drugs, 2017, 35, 545-555.	2.6	3
150	WP-1034, a Novel Jak-Stat Inhibitor, Has Proapoptotic and Antileukemic Activity in Acute Myeloid Leukemia (AML) Cell Lines and AML Patient Samples.. Blood, 2004, 104, 2528-2528.	1.4	3
151	The effect of new anthracycline derivatives on the induction of apoptotic processes in human neoplastic cells. Folia Histochemica Et Cytobiologica, 2004, 42, 127-30.	1.5	3
152	X-ray wavefunction refinement and comprehensive structural studies on bromo-substituted analogues of 2-deoxy-<scp>d</scp>-glucose in solid state and solution. RSC Advances, 2022, 12, 8345-8360.	3.6	3
153	Non-Cross-Resistant Anthracyclines with Reduced Basicity and Increased Stability of the Glycosidic Bond. ACS Symposium Series, 1994, , 14-46.	0.5	2
154	Targeting BCR-ABL and Its Downstream Signaling Cascade as Therapy for Chronic Myelogenous Leukemia.. Blood, 2004, 104, 2964-2964.	1.4	1
155	WP-1066, a Next-Generation Member of JAK-Stat Inhibitors, Induces Cell Cycle Arrest, Abrogates Proliferation, and Induces Apoptosis of Acute Myeloid Leukemia (AML) Cells.. Blood, 2004, 104, 1169-1169.	1.4	1
156	The Use of Liposomes as Carriers of Lipophilic Anthracycline Antibiotics. Journal of Liposome Research, 1994, 4, 555-573.	3.3	0